Drug class
Antiviral-HIV (Antiretroviral) Protease Inhibitors
Antiviral-HIV (antiretroviral) protease inhibitors constitute a therapeutic class of medications used primarily in combination antiretroviral therapy for the management and treatment of human immunodeficiency virus type 1 (HIV-1) infection. Read more about Antiviral-HIV (Antiretroviral) Protease Inhibitors
32 drugs in this class 20 manufacturers
Drugs in Antiviral-HIV (Antiretroviral) Protease Inhibitors
LOPINAVIR-RITONAVIR (lopinavir/ritonavir)
FOSAMPRENAVIR CALCIUM
ATAZANAVIR SULFATE
ATAZANAVIR SULFATE
SYMTUZA (darunavir eth/cobicistat/emtricitabine/tenofovir alafenamide)
VIRACEPT (nelfinavir mesylate)
ATAZANAVIR SULFATE
DARUNAVIR
Antiviral-HIV (antiretroviral) protease inhibitors constitute a therapeutic class of medications used primarily in combination antiretroviral therapy for the management and treatment of human immunodeficiency virus type 1 (HIV-1) infection.
These agents function by binding selectively to the active site of the viral HIV protease enzyme, which prevents the essential cleavage of nascent Gag and Gag-Pol precursor polyproteins.
By disrupting this critical maturation step during viral replication, the drugs prevent the formation of mature, infectious virions, thereby lowering viral load and impeding progression to acquired immunodeficiency syndrome (AIDS).
-
fda.gov
Antiviral-HIV (antiretroviral) protease inhibitors constitute a therapeutic class of medications used primarily in combination antiretroviral therapy for the management and treatment of human immunodeficiency virus type 1 (HIV-1) infection
-
nih.gov
Antiviral-HIV (antiretroviral) protease inhibitors constitute a therapeutic class of medications used primarily in combination antiretroviral therapy for the management and treatment of human immunodeficiency virus type 1 (HIV-1) infection These agents function by binding selectively to the active site of the viral HIV protease enzyme, which prevents the essential cleavage of nascent Gag and Gag-Pol precursor polyproteins By disrupting this critical maturation step during viral replication, the ...
-
fda.gov
These agents function by binding selectively to the active site of the viral HIV protease enzyme, which prevents the essential cleavage of nascent Gag and Gag-Pol precursor polyproteins By disrupting this critical maturation step during viral replication, the drugs prevent the formation of mature, infectious virions, thereby lowering viral load and impeding progression to acquired immunodeficiency syndrome (AIDS)
-
hiv.gov
By disrupting this critical maturation step during viral replication, the drugs prevent the formation of mature, infectious virions, thereby lowering viral load and impeding progression to acquired immunodeficiency syndrome (AIDS)
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.